Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05518578 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
A Phase 2 study, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05518578 is a Phase 2 study that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT05518578, a Phase 2 study, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
Interventions
- DRUG SPN-817
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05518578
The ClinicalTrials.gov registry entry for NCT05518578 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPN-817 is the first listed.
NCT05518578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05518578 about?
NCT05518578 is a clinical study titled "Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy". This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
What is the current status of trial NCT05518578?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-02-07. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT05518578?
The interventions under investigation include: SPN-817 (DRUG).
Who is sponsoring clinical trial NCT05518578?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.